With the recent improvements in the stability of RNA, nanoparticle technology, and targeted delivery, RNAi-based therapy is expected to arise as a promising approach to target the EGFR/PI3K/AKT/mTOR signaling specifically and effectively in HCC in vivo. The gene discussed is AKT1; the disease is hepatocellular carcinoma.